These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 38194968)

  • 1. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
    Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
    Cell; 2024 Feb; 187(3):585-595.e6. PubMed ID: 38194968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants.
    Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
    bioRxiv; 2023 Sep; ():. PubMed ID: 37745517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continued evasion of neutralizing antibody response by Omicron XBB.1.16.
    Faraone JN; Qu P; Zheng YM; Carlin C; Jones D; Panchal AR; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    Cell Rep; 2023 Oct; 42(10):113193. PubMed ID: 37777967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
    Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
    Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
    Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
    Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants.
    Li P; Faraone JN; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Xu K; Liu SL
    Cell Rep; 2024 Aug; 43(8):114520. PubMed ID: 39024099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal AR; Saif LJ; Oltz EM; Zhang B; Zhou T; Xu K; Gumina RJ; Liu SL
    Cell Rep; 2023 May; 42(5):112443. PubMed ID: 37104089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion.
    Li P; Liu Y; Faraone J; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu SL
    bioRxiv; 2024 Mar; ():. PubMed ID: 38559216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
    He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
    Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion.
    Li P; Faraone JN; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Xu K; Liu SL
    bioRxiv; 2024 May; ():. PubMed ID: 38826376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.
    Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A
    Virology; 2024 Jul; 595():110067. PubMed ID: 38653156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.
    Liu C; Zhou D; Dijokaite-Guraliuc A; Supasa P; Duyvesteyn HME; Ginn HM; Selvaraj M; Mentzer AJ; Das R; de Silva TI; Ritter TG; Plowright M; Newman TAH; Stafford L; Kronsteiner B; Temperton N; Lui Y; Fellermeyer M; Goulder P; Klenerman P; Dunachie SJ; Barton MI; Kutuzov MA; Dushek O; ; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR
    Cell Rep Med; 2024 May; 5(5):101553. PubMed ID: 38723626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
    Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
    Faraone JN; Wang X; Qu P; Zheng YM; Vincent E; Xu H; Liu SL
    J Med Virol; 2024 Mar; 96(3):e29520. PubMed ID: 38528837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.